Varnotech Biopharm

Varnotech Biopharm, operating under the legal name Beijing Varnotech Biopharm Co., Ltd. (北京华诺泰生物医药科技有限公司), is a privately held biotechnology company established in January 2019 by its founder and chairman, Mr. Wang Hailong. The company focuses on the research, development, and industrialization of innovative human vaccines and novel adjuvants.

The company operates on a strategic "one center, two bases" model. Its headquarters and research and development center are located in Beijing, while it has established a novel adjuvant production base in Chengdu, Sichuan, and a human vaccine manufacturing base in Taizhou, Jiangsu. This structure supports its goal of addressing critical gaps in China's vaccine industry, particularly concerning novel adjuvants.

Varnotech's core business revolves around developing a pipeline of preventive vaccines. Key candidates include a recombinant herpes zoster vaccine and an influenza vaccine, both of which are in clinical research stages. The pipeline also features a respiratory syncytial virus (RSV) vaccine in the pilot study phase. A significant differentiator for Varnotech is its in-house development and manufacturing of novel adjuvants, which are components that enhance the immune response to a vaccine. The company has developed adjuvants like QS-21 and 3D-MLA and is capable of producing various types including liposomes, aluminum-based adjuvants, and water-in-oil adjuvants, which has the potential to reduce reliance on foreign suppliers.

The company has successfully secured multiple rounds of financing to fuel its growth and clinical programs. In March 2024, Varnotech announced the completion of a ¥600 million Series B funding round. This capital is earmarked for advancing the clinical trials of its herpes zoster and influenza vaccines and for the construction of its vaccine and adjuvant production facilities. The company's recombinant herpes zoster vaccine is projected for a 2027 market launch, with its production facility expected to be completed in 2025.

Keywords: vaccine development, novel adjuvants, biotechnology, herpes zoster vaccine, influenza vaccine, respiratory syncytial virus, RSV, recombinant protein vaccines, adjuvant technology, biopharmaceutical, clinical trials, vaccine manufacturing, QS-21, 3D-MLA, liposome adjuvants, immunotherapy, preventive medicine, life sciences, China biotech, Wang Hailong